BridgeBio LLC
421 Kipling Street
Palo Alto
California
94301
United States
Tel: 650-391-9740
Website: http://bridgebio.com/
Email: info@bridgebio.com
About BridgeBio LLC
We focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. Our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting R&D with expert capabilities and placing them in a value maximizing corporate structure.
Hope through rigorous science.
103 articles with BridgeBio LLC
-
BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types
11/19/2021
BridgeBio Pharma, Inc. announced they have entered into a strategic collaboration to co-develop and co-commercialize a potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) with the hope of providing an effective new therapy for patients with difficult-to-treat tumors.
-
BridgeBio Pharma, Inc. Secures Up to $750 Million in Non-Dilutive Debt Financing
11/18/2021
BridgeBio Pharma, Inc. today announced that it has executed a definitive credit facility agreement with a syndicate of lenders for up to $750.0 million in financing.
-
Based on BridgeBio's current pipeline of programs, this total amount will be sufficient to carry over 30 drug development and discovery programs well into 2024.
-
After 32 years, gene therapy pioneer Guangping Gao, Ph.D., is finally seeing the fruits of the doctoral thesis research he started in 1989.
-
Top 12 Biotech Companies Hiring Now
11/4/2021
According to a recent BioSpace survey, 80% of non-vaccinated respondents said they would resign if their employer put forth a vaccine mandate. This may result in some additional candidates hitting the market. Start your job search now to get ahead of the competition! -
Monday was a big day for LianBio, as the Shanghai-based company launched on the Nasdaq with an impressive $325 million initial public offering (IPO).
-
BridgeBio Pharma Announces Collaborations with Columbia University and Mount Sinai to Develop Potential Therapies for Genetic Diseases and Cancers
10/29/2021
- The new agreements mean BridgeBio has collaborations with 25 leading academic institutions focused on genetic disease and precision oncology
-
Takeda entered into a licensing pact with Poseida, Spark entered into a licensing agreement with CombiGene AB, while BridgeBio Pharma announced plans for its second annual R&D Day.
-
FDA has been actively greenlighting a number of efforts over the last few days to push therapies for rare or serious diseases that have largely unmet medical needs. Here's a look.
-
BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid Tumors
8/25/2021
LianBio today announced the first patient has been treated in a Phase 2a clinical trial of infigratinib in patients with locally advanced or metastatic gastric cancer
-
BridgeBio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to its Board of Directors
8/18/2021
BridgeBio Pharma, Inc. today announced that it has added three new independent directors to its board
-
BridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results and Business Update
8/5/2021
BridgeBio Pharma, Inc. today reported its financial results for the second quarter ended June 30, 2021 and provided an update on the Company's operations.
-
The companies will co-finance a clinical study to test the combination of SHP2 inhibitor BBP-398 and OPDIVO in treating patients with advanced solid tumors KRAS mutations.
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - June 14, 2021
6/14/2021
BridgeBio Pharma, Inc. announced that on June 1, 2021, the compensation committee of BridgeBio’s board of directors granted 21 new employees restricted stock units for an aggregate of 47,963 shares of the Company’s common stock.
-
The FDA approves Truseltiq for patients with previously-treated locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement.
-
BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1
6/1/2021
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, announced that the U.S. Food and Drug Administration granted Fast Track designation for encaleret for the treatment of autosomal dominant hypocalcemia.
-
Wang, who has played a key role in the development of more than 25 innovative medicines at Eli Lilly and GlaxoSmithKline, made him the ideal fit for the company’s next chapter.
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 14, 2021
5/14/2021
BridgeBio Pharma, Inc., a clinical-stage biopharmaceutical company focused on genetic diseases, announced that on May 4, 2021, the compensation committee of BridgeBio’s board of directors granted 27 new employees restricted stock units for an aggregate of 70,949 shares of the Company’s common stock.
-
BridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update
5/6/2021
– Received U.S. Food and Drug Administration (FDA) approval for NULIBRY™ (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency ( MoCD) Type A – Reported pr oof-of-concept data of encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) –
-
BridgeBio Pharma, Inc. and UC Davis Establish Collaboration to Transform Research into Potential Therapies for Genetically Driven Diseases
4/13/2021
BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with the University of California, Davis (UC Davis), to advance research and the development of investigational medicines for patients with genetically driven conditions and cancers.